Publications by authors named "J Tota"
Background: Gay, bisexual, and other men who have sex with men (gbMSM) have a higher risk of human papillomavirus (HPV) infection and related diseases and would benefit from preventive measures such as HPV vaccination. We assessed the association between HPV vaccination and anal HPV infection in HIV-negative gbMSM and gbMSM living with HIV from the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection study.
Methods: Participants attended 7 visits over 12 months where they provided a nurse-collected anal sample and self-completed a questionnaire on risk factors and HPV vaccination.
Article Synopsis
- Juvenile- and adult-onset recurrent respiratory papillomatosis (JORRP and AORRP) are rare and serious medical conditions caused by HPV, leading to growths in the throat and can even be deadly.
- The main treatment for these conditions is surgery, but getting vaccinated against HPV can help prevent infection.
- A new model shows that since the HPV vaccine was introduced in the US, it has saved many lives and reduced the number of cases significantly, with expected cases dropping to very low numbers by 2040.
Article Synopsis
- Nine-valent human papillomavirus (9vHPV) vaccines can be given in two doses, and this study explores the effects of extending the time between doses beyond the typical 6 to 12 months.
- The study involved 146 adolescents who received their second 9vHPV dose between 12 to 53 months after the first dose, and results showed that antibody levels increased significantly after the second dose, with all participants showing a positive response a month later.
- Adverse events were mostly mild, such as injection site reactions, and no serious side effects were reported, suggesting that longer intervals between doses are safe and effective for the 9vHPV vaccination.
In Norway, single-cohort vaccination with quadrivalent human papillomavirus (qHPV) vaccine targeting 12-year-old girls took place in 2009-2016. In 2020, the oldest vaccinated cohort was 23 years old and had approached the age where risk of being diagnosed with cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increases rapidly. The aim of this cohort study was to assess direct qHPV vaccine effectiveness (VE) against CIN2+ among Norwegian women aged 16-30 years in 2007-2020.
View Article and Find Full Text PDFPrevious research has shown that women's use of a carrageenan gel reduces the risk of acquiring genital human papillomavirus (HPV) infections but does not help to clear existing ones. Although gel use may not result in complete clearance, it may decrease the viral load of HPV infections. We tested this hypothesis in the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) randomized controlled trial.
View Article and Find Full Text PDF